Clinical Study R0eveals Significant Dosing Variations and Outcome Risks for Antiplatelet Bridging Following Heart Procedures

New research from SCAI 2026 shows how varying doses of cangrelor impact MACE and bleeding risks post-PCI. Standardized bridging protocols are urgently needed.

By: AXL Media

Published: Apr 25, 2026, 9:38 AM EDT

Source: Information for this report was sourced from EurekAlert!

The Complexity of Perioperative Antiplatelet Management

Managing patients who require surgery shortly after a percutaneous coronary intervention (PCI) presents a significant clinical challenge, as doctors must balance the risk of blood clots against the potential for surgical bleeding. When oral antiplatelet therapies must be interrupted for a procedure, clinicians often turn to intravenous bridging agents like cangrelor to maintain platelet inhibition. This short-acting medication is designed to provide a temporary safety net, yet new real-world data suggest that the way this drug is administered in daily practice varies widely from established clinical trial protocols.

Substantial Variability in Real-World Dosing Patterns

A retrospective review of 222 patients across the United States reveals that standardized dosing for antiplatelet bridging remains elusive in modern cardiology. While the recommended bridging dose identified in randomized controlled trials is 0.75 mcg/kg/min, the study found that only a minority of patients receive this exact amount. Approximately 61.2% of patients were given infusion rates exceeding this benchmark, while 11.7% received lower doses. This inconsistency suggests that clinical decision-making regarding IV antiplatelet therapy is often individualized, leading to a broad spectrum of practical applications across different hospital systems.

Correlating Infusion Rates with Cardiovascular Events

The research indicates that the specific dose of cangrelor administered has a direct and measurable impact on the frequency of Major Adverse Cardiovascular Events (MACE). Patients receiving lower infusion rates, specifically those under 0.75 mcg/kg/min, experienced a significantly higher rate of adverse events at 19.2%. In contrast, those receiving the trial-validated dose of 0.75 mcg/kg/min saw the lowest event frequency at just 6.0%. These findings suggest that under-dosing during the critical bridging period may leave patients vulnerable to thrombotic complications during or after their subsequent surgeries.